Kim J.Villar Z.Jobe O.Rerks-Ngarm S.Pitisuttithum P.Nitayaphan S.O'Connell R.J.Ake J.A.Vasan S.Rao V.B.Rao M.Mahidol University2024-06-302024-06-302024-09-01Virology Vol.597 (2024)00426822https://repository.li.mahidol.ac.th/handle/20.500.14594/99256An important approach to stopping the AIDS epidemic is the development of a vaccine that elicits antibodies that block virus capture, the initial interactions of HIV-1 with the target cells, and replication. We utilized a previously developed qRT-PCR-based assay to examine the effects of broadly neutralizing antibodies (bNAbs), plasma from vaccine trials, and monoclonal antibodies (mAbs) on virus capture and replication. A panel of bNAbs inhibited primary HIV-1 replication in PBMCs but not virus capture. Plasma from RV144 and RV305 trial vaccinees demonstrated inhibition of virus capture with the HIV-1 subtype prevalent in Thailand. Several RV305 derived V2-specific mAbs inhibited virus replication. One of these RV305 derived V2-specific mAbs inhibited both virus capture and replication, demonstrating that it is possible to elicit antibodies by vaccination that inhibit virus capture and replication. Induction of a combination of such antibodies may be the key to protection from HIV-1 acquisition.Immunology and MicrobiologyArticleSCOPUS10.1016/j.virol.2024.1101582-s2.0-8519682403010960341